Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Erythropoietin - Dong-A ST

Drug Profile

Erythropoietin - Dong-A ST

Alternative Names: DA-3285; EPO - Dong-A ST; Eporon; Erythropoietin - Dong-A; Erythropoietin alfa

Latest Information Update: 18 May 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dong-A Pharmaceutical
  • Developer Dem Ilac; Dong-A Pharmaceutical
  • Class Antianaemics; Polyethylene glycols; Recombinant erythropoietins; Recombinant fusion proteins
  • Mechanism of Action Erythropoiesis stimulants; Erythropoietin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Anaemia

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 03 Feb 2016 Dong-A ST and Ajou University School of Medicine plan the phase II NIMBUS trial for Stroke in South Korea (IV) (NCT02603406)
  • 03 Feb 2016 Dong-A ST plans a pharmacokinetics/pharmacodynamics phase I trial in Healthy male volunteers in South Korea (SC) (NCT02580006)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top